Cargando…

Development and characterization of an indirect ELISA to detect SARS-CoV-2 spike protein-specific antibodies

The current Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) pandemic is a public health emergency of international concern. Sensitive and precise diagnostic tools are urgently needed. In this study, we developed a SARS-CoV-2 spike (S1) protein enzyme-linked immunosorbent assay (...

Descripción completa

Detalles Bibliográficos
Autores principales: Krähling, Verena, Halwe, Sandro, Rohde, Cornelius, Becker, Dirk, Berghöfer, Susanne, Dahlke, Christine, Eickmann, Markus, Ercanoglu, Meryem S., Gieselmann, Lutz, Herwig, Astrid, Kupke, Alexandra, Müller, Helena, Neubauer-Rädel, Petra, Klein, Florian, Keller, Christian, Becker, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831464/
https://www.ncbi.nlm.nih.gov/pubmed/33412174
http://dx.doi.org/10.1016/j.jim.2021.112958
_version_ 1783641627878752256
author Krähling, Verena
Halwe, Sandro
Rohde, Cornelius
Becker, Dirk
Berghöfer, Susanne
Dahlke, Christine
Eickmann, Markus
Ercanoglu, Meryem S.
Gieselmann, Lutz
Herwig, Astrid
Kupke, Alexandra
Müller, Helena
Neubauer-Rädel, Petra
Klein, Florian
Keller, Christian
Becker, Stephan
author_facet Krähling, Verena
Halwe, Sandro
Rohde, Cornelius
Becker, Dirk
Berghöfer, Susanne
Dahlke, Christine
Eickmann, Markus
Ercanoglu, Meryem S.
Gieselmann, Lutz
Herwig, Astrid
Kupke, Alexandra
Müller, Helena
Neubauer-Rädel, Petra
Klein, Florian
Keller, Christian
Becker, Stephan
author_sort Krähling, Verena
collection PubMed
description The current Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) pandemic is a public health emergency of international concern. Sensitive and precise diagnostic tools are urgently needed. In this study, we developed a SARS-CoV-2 spike (S1) protein enzyme-linked immunosorbent assay (ELISA) to detect SARS-CoV-2-specific antibodies. The SARS-CoV-2 S1 ELISA was found to be specific [97.8% (95% CI, 96.7% - 98.5%)], reproducible and precise (intra-assay coefficient of variability (CV) 5.3%, inter-assay CV 7.9%). A standard curve and the interpolation of arbitrary ELISA units per milliliter served to reduce the variability between different tests and operators. Cross-reactivity to other human coronaviruses was addressed by using sera positive for MERS-CoV- and hCoV HKU1-specific antibodies. Monitoring antibody development in various samples of twenty-three and single samples of twenty-nine coronavirus disease 2019 (COVID−19) patients revealed seroconversion and neutralizing antibodies against authentic SARS-CoV-2 in all cases. The comparison of the SARS-CoV-2 (S1) ELISA with a commercially available assay showed a better sensitivity for the in-house ELISA. The results demonstrate a high reproducibility, specificity and sensitivity of the newly developed ELISA, which is suitable for the detection of SARS-CoV-2 S1 protein-specific antibody responses.
format Online
Article
Text
id pubmed-7831464
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Authors. Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-78314642021-01-26 Development and characterization of an indirect ELISA to detect SARS-CoV-2 spike protein-specific antibodies Krähling, Verena Halwe, Sandro Rohde, Cornelius Becker, Dirk Berghöfer, Susanne Dahlke, Christine Eickmann, Markus Ercanoglu, Meryem S. Gieselmann, Lutz Herwig, Astrid Kupke, Alexandra Müller, Helena Neubauer-Rädel, Petra Klein, Florian Keller, Christian Becker, Stephan J Immunol Methods Article The current Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) pandemic is a public health emergency of international concern. Sensitive and precise diagnostic tools are urgently needed. In this study, we developed a SARS-CoV-2 spike (S1) protein enzyme-linked immunosorbent assay (ELISA) to detect SARS-CoV-2-specific antibodies. The SARS-CoV-2 S1 ELISA was found to be specific [97.8% (95% CI, 96.7% - 98.5%)], reproducible and precise (intra-assay coefficient of variability (CV) 5.3%, inter-assay CV 7.9%). A standard curve and the interpolation of arbitrary ELISA units per milliliter served to reduce the variability between different tests and operators. Cross-reactivity to other human coronaviruses was addressed by using sera positive for MERS-CoV- and hCoV HKU1-specific antibodies. Monitoring antibody development in various samples of twenty-three and single samples of twenty-nine coronavirus disease 2019 (COVID−19) patients revealed seroconversion and neutralizing antibodies against authentic SARS-CoV-2 in all cases. The comparison of the SARS-CoV-2 (S1) ELISA with a commercially available assay showed a better sensitivity for the in-house ELISA. The results demonstrate a high reproducibility, specificity and sensitivity of the newly developed ELISA, which is suitable for the detection of SARS-CoV-2 S1 protein-specific antibody responses. The Authors. Published by Elsevier B.V. 2021-03 2021-01-04 /pmc/articles/PMC7831464/ /pubmed/33412174 http://dx.doi.org/10.1016/j.jim.2021.112958 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Krähling, Verena
Halwe, Sandro
Rohde, Cornelius
Becker, Dirk
Berghöfer, Susanne
Dahlke, Christine
Eickmann, Markus
Ercanoglu, Meryem S.
Gieselmann, Lutz
Herwig, Astrid
Kupke, Alexandra
Müller, Helena
Neubauer-Rädel, Petra
Klein, Florian
Keller, Christian
Becker, Stephan
Development and characterization of an indirect ELISA to detect SARS-CoV-2 spike protein-specific antibodies
title Development and characterization of an indirect ELISA to detect SARS-CoV-2 spike protein-specific antibodies
title_full Development and characterization of an indirect ELISA to detect SARS-CoV-2 spike protein-specific antibodies
title_fullStr Development and characterization of an indirect ELISA to detect SARS-CoV-2 spike protein-specific antibodies
title_full_unstemmed Development and characterization of an indirect ELISA to detect SARS-CoV-2 spike protein-specific antibodies
title_short Development and characterization of an indirect ELISA to detect SARS-CoV-2 spike protein-specific antibodies
title_sort development and characterization of an indirect elisa to detect sars-cov-2 spike protein-specific antibodies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831464/
https://www.ncbi.nlm.nih.gov/pubmed/33412174
http://dx.doi.org/10.1016/j.jim.2021.112958
work_keys_str_mv AT krahlingverena developmentandcharacterizationofanindirectelisatodetectsarscov2spikeproteinspecificantibodies
AT halwesandro developmentandcharacterizationofanindirectelisatodetectsarscov2spikeproteinspecificantibodies
AT rohdecornelius developmentandcharacterizationofanindirectelisatodetectsarscov2spikeproteinspecificantibodies
AT beckerdirk developmentandcharacterizationofanindirectelisatodetectsarscov2spikeproteinspecificantibodies
AT berghofersusanne developmentandcharacterizationofanindirectelisatodetectsarscov2spikeproteinspecificantibodies
AT dahlkechristine developmentandcharacterizationofanindirectelisatodetectsarscov2spikeproteinspecificantibodies
AT eickmannmarkus developmentandcharacterizationofanindirectelisatodetectsarscov2spikeproteinspecificantibodies
AT ercanoglumeryems developmentandcharacterizationofanindirectelisatodetectsarscov2spikeproteinspecificantibodies
AT gieselmannlutz developmentandcharacterizationofanindirectelisatodetectsarscov2spikeproteinspecificantibodies
AT herwigastrid developmentandcharacterizationofanindirectelisatodetectsarscov2spikeproteinspecificantibodies
AT kupkealexandra developmentandcharacterizationofanindirectelisatodetectsarscov2spikeproteinspecificantibodies
AT mullerhelena developmentandcharacterizationofanindirectelisatodetectsarscov2spikeproteinspecificantibodies
AT neubauerradelpetra developmentandcharacterizationofanindirectelisatodetectsarscov2spikeproteinspecificantibodies
AT kleinflorian developmentandcharacterizationofanindirectelisatodetectsarscov2spikeproteinspecificantibodies
AT kellerchristian developmentandcharacterizationofanindirectelisatodetectsarscov2spikeproteinspecificantibodies
AT beckerstephan developmentandcharacterizationofanindirectelisatodetectsarscov2spikeproteinspecificantibodies